On behalf of Colorado Department of Health Care Policy and Financing,

On January 9, 2024 the P&T committee will review the products on the attached document <COM\_Classes\_For\_Review\_January\_2024.pdf>. In preparation for this review, on behalf of Health First Colorado, Provider Synergies (PS) and Magellan Medicaid Administration (MMA) are requesting supplemental rebate offers for these products.

We have also attached the PDL Drug Class Announcement to show all drugs that will be included in the drug class reviews at the upcoming P&T Committee meeting for Health First Colorado <PDL Drug Class Review Anouncement.pdf>.

Please note, despite the Off Cycle Insulin Request on Wednesday, October 25, 2023, Colorado will be reviewing these products as part of the January P&T Review cycle. Please resubmit any offers on the attached Offer Form as a part of this solicitation.

These drug classes will be reviewed at the January 9, 2024 P&T Committee meeting from 1-5pm. The meeting will be held virtually via webinar. Registration link will be announced at a later date, on the P&T Committee website <https://www.colorado.gov/pacific/hcpf/pharmacy-and-therapeutics-committee>

1. Email dossier and any other pertinent clinical data to Greg Miller, PharmD via email ([greg.l.miller@state.co.us](mailto:greg.l.miller@state.co.us)).
2. Interested parties who want to present at the meeting shall give advanced notice, and provide a one-page summary of the clinical information that will be presented, by **5pm MT on January 2, 2024**, to Jessica Czechowski, Pharmacist Account Executive ([jlczechowski@magellanhealth.com](mailto:jlczechowski@magellanhealth.com)) and carbon copy Greg Miller, PharmD, PDL & Clinical Strategy Pharmacist ([greg.l.miller@state.co.us](mailto:greg.l.miller@state.co.us)). Policies surrounding stakeholder comment can be found at: <https://www.colorado.gov/pacific/hcpf/pharmacy-and-therapeutics-committee>.

Please be aware that an additional solicitation for Long-Acting Injectable Antipsychotics will be sent to applicable manufacturers. Long-Acting Injectable Antipsychotics will continue to be listed on Appendix P and will not be reviewed at the upcoming P&T meeting (they will not be moving to the PDL).

The preferred contract price/discount for Health First Colorado is the Guaranteed Net Unit Price (GNUP) based on Wholesale Acquisition Cost (WAC). GNUP is calculated as:

**GNUP = WAC Price per Unit - Federal Unit Rebate Amount - Supplemental Rebate Amount.**

The GNUP represents the value that will determine the supplemental rebate amount each quarter, along with the WAC price and Federal Unit Rebate Amount in effect for that quarter, throughout the term of the contract. The GNUP is also the value that will appear on the supplemental rebate contract.

All supplemental rebate offers must be submitted via the Provider Synergies Secure FTP site at (<https://secureftp.providersynergies.com/>) using the Offer Form available for download at:

<https://www1.magellanrx.com/preferred-drug-list-programs/manufacturer-hub/single-state-programs/>

Only those offers submitted to Provider Synergies through our Secure FTP site and using **this** Offer Form will be presented to the division for review and consideration.

Please save the Offer Form file to your local PC and follow the instructions for the completion and submission of the form. All best and final supplemental rebate offers must be submitted to the Provider Synergies Secure FTP site by:

**5:00 p.m. EST on Friday, December 8, 2023**

The following information is provided to assist you in completing and submitting your Offer Form, in addition to the instructions included on the Offer Form itself:

1. Please direct questions regarding how to complete the Offer Form to Cole Anderson ([andersonc2@magellanhealth.com](mailto:andersonc2@magellanhealth.com)).
2. For detailed written instructions on how to access and upload your Offer Form to the Secure FTP site, please contact Cole Anderson ([andersonc2@magellanhealth.com](mailto:andersonc2@magellanhealth.com)). Requests for new user names and passwords, or requests to re-set existing user names and passwords may also be submitted by e-mail to Cole Anderson. User names and passwords will not be provided over the telephone.
3. Do not change the column header names, add or delete columns or rows, or modify any formats on the Offer Form. Doing so may render your Offer Form information unrecognizable by our systems.
4. Offer language in the offer is limited to 220 characters.
5. Prior to submitting, please re-name the Offer Form file as COM [Your Company] Offer Form.xls. Using any other naming convention or saving the file as a type other than .xls may render your Offer Form information unrecognizable by our systems. Please limit your company’s name to 15 characters, abbreviating or truncating if necessary.
6. A confirmation of receipt will be sent to the e-mail address designated on the Preparer Information tab of each Offer Form when the file is downloaded from the Secure FTP site to our internal servers (*not* when the file is uploaded). Allow at least 4 hours from the time of submission to the FTP site for the generation of the confirmation of receipt.

Supplemental rebates for those products selected for the Preferred Drug List will begin to accrue April 1, 2024.

Regards,